Our site uses cookies to make navigation as function as possible, including “third party” cookies and “profiling cookies” designed to tailor
on-line contents to suit the preferences expressed while surfing the internet. Should you wish to receive more information, or deny your
consent to some or all cookies, click here. If you proceed with browsing this website, you will be consenting to the use of all cookies.

Menarini Group - Global Reach

Menarini Worldwide

As the leading Italian pharmaceutical group, we are headquartered in Florence, Italy, and extend to over 100 countries around the world through an extensive network of representatives, distributors and local partners. We continue to expand our global footprint across Asia-Pacific, Africa and the Middle East, Europe, and Central and South America, to rejuvenate lives and to better meet the healthcare needs around the world.

Central and South America

We established our presence in Central America in the early 1980s. From Guatemala, Dominican Republic, Nicaragua, Honduras, Costa Rica, Panama and El Salvador, we have grown to be among the top five companies in the region today. In South America, affiliate offices were opened in Argentina and Mexico in early 2001 and in 2008 respectively. We have since introduced various products to the Columbia and Ecuador markets, with aims to introduce more in the near future.


We are one of the leading pharmaceutical groups with significant presence across Europe – Austria, Benelux, France, Germany, United Kingdom, Greece, Ireland, Portugal, Spain, Turkey and Switzerland. Having also established a strong foothold in the Eastern and Central European markets, today we rank 6th in the region, 2nd in Russia and Kazakhstan, and we are also a market leader in the Baltic States, Ukraine and Belarus.


We entered a joint venture in South Africa, with plans to consolidate the market with the launch of new products currently under registration. At the same time, we are also consolidating our presence throughout North Africa, in Morocco, Tunisia, Algeria, Libya and Egypt, and in French-speaking Africa. In the Middle East, we are progressively gaining important market share, with a focus on Jordan, Lebanon, Syria, Saudi Arabia and the Gulf region.


We first forayed into Asia through a joint venture in India in 1995. Since then, we have steadily expanded in the region through strong partner distributorships and established a direct presence in China through our Germany-based subsidiary, Berlin-Chemie. In the acquisition of the Invida Group, subsequently renamed Menarini Asia-Pacific, in November 2011, we created a strong synergistic relationship that provided our global partners with confidence in our combined strengths to deliver in the region.

Manufacturing Sites

We have 16 manufacturing sites globally, operating in Florence, L’Aquila, Berlin, Dresden, Barcelona, Istanbul, Kaluga, Pisa, Lomagna, Guatemala, Shannon and Jakarta – the first such site in the Asia-Pacific region. Together, they produce millions of pharmaceutical products yearly for distribution to markets all over the world.

Find out more about our manufacturing sites here.

Research Centres

Menarini Research dedicates itself to the research and development of our pharmaceutical products, from its initial phases until drug registration. Menarini Biotech and Menarini’s Centre for Research and Development jointly ensure the continuous development of target therapies and continue to define new approaches to research.

Menarini Group also remain committed to the advancement of target therapies through initiatives globally, including through the setting up of Menarini Biomarkers Singapore (MBS) in 2014. It collaborates with public research institutions, to identify and develop diagnostic and prognostic biomarkers for precision or personalised medicine.

Find out more about our research centres and research programmes here, and MBS here.


A non-profit institution founded in 1976 to promote research...



Find our companies



Daiichi Sankyo and Menarini Enter into Exclusive Licensing Agreement for Commercializing LIXIANA® in the Philippines, Malaysia and Singapore